Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)
Non-small Cell Lung Cancer Patients
Conditions: official terms
Carcinoma, Non-Small-Cell Lung
Study Type
Study Phase
Study Design
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment
Name: 18F-FDG-PET scan
Type: Procedure
Overall Status
Erlotinib, an anti-cancer agent targeting the epidermal growth factor receptor (EGFR), is an active treatment of patients with non-small cell lung cancer (NSCLC). Effect of treatment is primary seen in patients harboring a mutation in the EGFR. However, 10-15% of patients does not harbor a mutation but respond as well. Identifying these patients is a problem and methods are lacking.

Studies have shown that an early 18F FDG-PET might can predict response and outcome in these patients, but further studies are needed to confirm these findings.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Lung Cancer patients with non-small cell histology and stage IV disease

- candidate for erlotinib treatment as first/ second/ third line of treatment

Exclusion Criteria:

- pregnancy

- severe dyspnoea
Aarhus University Hospital
Aarhus, Jylland, Denmark
Status: Recruiting
Contact: Anne Winther Larsen, MD - anlarsen@rm.dk
Start Date
April 2013
University of Aarhus
University of Aarhus
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page